78 related articles for article (PubMed ID: 27628794)
1. Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer.
Taneja SS
J Urol; 2016 Oct; 196(4):1124. PubMed ID: 27628794
[No Abstract] [Full Text] [Related]
2. AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?
Montgomery RB; Plymate SR
JAMA Oncol; 2016 Nov; 2(11):1450-1451. PubMed ID: 27261766
[No Abstract] [Full Text] [Related]
3. Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance.
Fenner A
Nat Rev Urol; 2016 Dec; 13(12):695. PubMed ID: 27779227
[No Abstract] [Full Text] [Related]
4. Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56: AR-V7 Testing: What's in it for the Patient?
Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
Eur Urol; 2017 Dec; 72(6):e168-e169. PubMed ID: 28688614
[No Abstract] [Full Text] [Related]
5. AR-V7 detection guides treatment.
Romero D
Nat Rev Clin Oncol; 2018 Sep; 15(9):533. PubMed ID: 30018408
[No Abstract] [Full Text] [Related]
6. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
7. Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol 2017;35:2149-56. AR-V7 Testing: What's in it for the Patient?: Estimating the Clinical Utility of Blood-based AR-V7 Testing in Prostate Cancer.
Luo J; Luber B; Wang H; Antonarakis ES
Eur Urol; 2017 Dec; 72(6):e170-e171. PubMed ID: 28693939
[No Abstract] [Full Text] [Related]
8. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
[TBL] [Abstract][Full Text] [Related]
9. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
10. Clinical decision-making with AR-V7.
Thoma C
Nat Rev Urol; 2019 Dec; 16(12):694. PubMed ID: 31690843
[No Abstract] [Full Text] [Related]
11. AR-v7 liquid biopsy for treatment stratification in prostate cancer: how close are we?
Fletcher C
Curr Opin Urol; 2017 Sep; 27(5):500-509. PubMed ID: 28590268
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
13. Refining the Assessment and Implications of AR-V7 in Castrate-resistant Prostate Cancer.
Crumbaker M; Savdie R; Joshua AM
Eur Urol; 2018 May; 73(5):736-737. PubMed ID: 29162351
[No Abstract] [Full Text] [Related]
14. Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.
Lokhandwala PM; Riel SL; Haley L; Lu C; Chen Y; Silberstein J; Zhu Y; Zheng G; Lin MT; Gocke CD; Partin AW; Antonarakis ES; Luo J; Eshleman JR
J Mol Diagn; 2017 Jan; 19(1):115-125. PubMed ID: 27916435
[TBL] [Abstract][Full Text] [Related]
15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer.
Sartor O; Dong Y
Asian J Androl; 2015; 17(3):439-40. PubMed ID: 25532583
[TBL] [Abstract][Full Text] [Related]
17. Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Cronauer MV; Merseburger AS; Hoda MR
Eur Urol; 2017 Apr; 71(4):e105-e106. PubMed ID: 27663049
[No Abstract] [Full Text] [Related]
18. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker.
Stone L
Nat Rev Urol; 2016 Aug; 13(8):433. PubMed ID: 27349368
[No Abstract] [Full Text] [Related]
19. The potential of AR-V7 as a therapeutic target.
Uo T; Plymate SR; Sprenger CC
Expert Opin Ther Targets; 2018 Mar; 22(3):201-216. PubMed ID: 29417861
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
